- Previous Close
8,120.00 - Open
8,000.00 - Bid 7,890.00 x --
- Ask 8,000.00 x --
- Day's Range
7,740.00 - 8,250.00 - 52 Week Range
6,950.00 - 12,380.00 - Volume
84,961 - Avg. Volume
89,495 - Market Cap (intraday)
121.12B - Beta (5Y Monthly) 1.07
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 14, 2025 - May 19, 2025
- Forward Dividend & Yield 50.00 (0.63%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
--
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. The company was founded in 1959 and is headquartered in Seoul, South Korea.
www.jeilpharm.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 002620.KS
View MorePerformance Overview: 002620.KS
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002620.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002620.KS
View MoreValuation Measures
Market Cap
121.12B
Enterprise Value
200.45B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.16
Price/Book (mrq)
0.39
Enterprise Value/Revenue
0.26
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-6.56%
Return on Assets (ttm)
-0.79%
Return on Equity (ttm)
-15.82%
Revenue (ttm)
779.82B
Net Income Avi to Common (ttm)
-51.16B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
75.88B
Total Debt/Equity (mrq)
35.48%
Levered Free Cash Flow (ttm)
11.67B